Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 known ✓ | Q9Y5N1 | 4/20 | 0.65 |
| ▸ | MAOA known ✓ | P21397 | 3/20 | 0.65 |
| ▸ | HTR3A known ✓ | P46098 | 1/20 | 0.65 |
| ▸ | SCN1A known ✓ | P35498 | 4/20 | 0.62 |
| ▸ | SCN2A known ✓ | Q99250 | 4/20 | 0.62 |
| ▸ | SCN3A known ✓ | Q9NY46 | 4/20 | 0.62 |
| ▸ | KCNH2 known ✓ | Q12809 | 3/20 | 0.50 |
| ▸ | SIGMAR1 known ✓ | Q99720 | 2/20 | 0.50 |
| ▸ | SLC6A3 known ✓ | Q01959 | 2/20 | 0.50 |
| ▸ | DRD4 known ✓ | P21917 | 1/20 | 0.50 |
| ▸ | ACHE known ✓ | P22303 | 1/20 | 0.50 |
| ▸ | HRH2 known ✓ | P25021 | 1/20 | 0.50 |
| ▸ | HTR2A known ✓ | P28223 | 1/20 | 0.50 |
| ▸ | HTR2C known ✓ | P28335 | 1/20 | 0.50 |
| ▸ | HRH1 known ✓ | P35367 | 1/20 | 0.50 |
| ▸ | DRD3 known ✓ | P35462 | 1/20 | 0.50 |
| ▸ | HTR2B known ✓ | P41595 | 1/20 | 0.50 |
| ▸ | SCN7A known ✓ | Q01118 | 1/20 | 0.50 |
| ▸ | SCN5A known ✓ | Q14524 | 1/20 | 0.50 |
| ▸ | SCN9A known ✓ | Q15858 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6677 | 0.99 | HRH3 (0.67) | BLMNPSR1HRH3TSHRMAOA | |
| Water SCHEMBL8171709 | 0.97 | HRH3 (0.65) | BLMNPSR1HRH3TSHRMAOA | |
| Choline SCHEMBL3808986 | 0.89 | HRH3 (0.55) | BLMNPSR1HRH3TSHRMAOA | |
| Hydrochloric Acid SCHEMBL9543350 | 0.86 | BLM (0.72) | BLMNPSR1HRH3TSHRMAOA | |
| SCHEMBL4295410 | 0.85 | HRH3 (0.68) | BLMNPSR1HRH3TSHRMAOA | |
| SCHEMBL94128 | 0.85 | HRH3 (0.68) | BLMNPSR1HRH3TSHRMAOA | |
| SCHEMBL3840896 | 0.85 | SMN1; SMN2 (0.53) | BLMNPSR1HRH3TSHRMAOA | |
| SCHEMBL9576578 | 0.84 | HRH3 (0.71) | BLMNPSR1HRH3TSHRMAOA | |
| SCHEMBL174306 | 0.83 | MAOA (0.49) | BLMNPSR1HRH3TSHRMAOA | |
| SCHEMBL6616028 | 0.83 | TSHR (0.52) | BLMNPSR1HRH3TSHRMAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1600 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260097044-A1 | ION PAIR LIQUID CRYSTAL FORMULATIONS FOR LONG-ACTING INJECTABLES OF POORLY SOLUBLE DRUGS | FORDOZ PHARMA CORP. (US) | 2026-04-09 | — | — | US | claimed |
| US-20250269093-A1 | METHODS OF ENHANCING ANTIMICROBIAL EFFICACY OF LOCAL ANESTHETICS | Chinook Contract Research Inc. (CA) | 2025-08-28 | — | — | US | claimed |
| CN-119738515-A | Method for simultaneously determining 6 benzoic acid genotoxic impurities in chloroprocaine hydrochloride or preparation thereof by adopting ESI-LC-MSMS technology | 南京清科医药科技有限公司 | 2025-04-01 | — | — | CN | claimed |
| CN-119707723-A | Preparation method of chloroprocaine hydrochloride | 浙江昂利泰制药有限公司 | 2025-03-28 | — | — | CN | claimed |
| WO-2025015419-A1 | METHODS OF ENHANCING ANTIMICROBIAL EFFICACY OF LOCAL ANESTHETICS | Chinook Contract Research Inc. (CA) | 2025-01-23 | — | — | WO | claimed |
| CN-119241378-A | Synthesis method of chloroprocaine hydrochloride intermediate impurity | 南京斯泰尔医药科技有限公司 | 2025-01-03 | — | — | CN | claimed |
| CN-119241383-A | Efficient synthesis method of chloroprocaine hydrochloride | 南京斯泰尔医药科技有限公司 | 2025-01-03 | — | — | CN | claimed |
| CN-119192013-A | Synthesis method of chloroprocaine hydrochloride impurity | 南京斯泰尔医药科技有限公司 | 2024-12-27 | — | — | CN | claimed |
| CN-119015216-A | Gel type nanometer photosensitizer for local skin surface or cavity and preparation method and application thereof | 镇江华越医疗器械销售有限责任公司 | 2024-11-26 | — | — | CN | claimed |
| CN-118416028-A | Oral mucosa repair film and preparation method and application thereof | 宁波市第二医院 | 2024-08-02 | — | — | CN | claimed |
| EP-0608322-A1 | ENHANCED SKIN PENETRATION SYSTEM FOR IMPROVED TOPICAL DELIVERY OF DRUGS | RICHARDSON-VICKS, INC. (US) | 1994-08-03 | — | — | EP | claimed |
| EP-0608320-A1 | ENHANCED SKIN PENETRATION SYSTEM FOR IMPROVED TOPICAL DELIVERY OF DRUGS | RICHARDSON-VICKS, INC. (US) | 1994-08-03 | — | — | EP | claimed |
| US-5322689-A | Topical aromatic releasing compositions | THE PROCTER & GAMBLE COMPANY (US) | 1994-06-21 | — | — | US | claimed |
| WO-1994002176-A1 | PHARMACEUTICAL COMPOSITION FOR TOPICAL USE CONTAINING A CROSSLINKED CATIONIC POLYMER AND AN ALKOXYLATED ETHER | THE PROCTER & GAMBLE COMPANY (US) | 1994-02-03 | — | — | WO | claimed |
| CN-1079896-A | The compositions of topical aromatic releasing | RICHARDSON VICKS INC (US) | 1993-12-29 | — | — | CN | claimed |
| WO-1993017655-A1 | TOPICAL AROMATIC RELEASING COMPOSITIONS | RICHARDSON VICKS INC. (US) | 1993-09-16 | — | — | WO | claimed |
| CN-1072863-A | Be used to improve the dermal osmosis system of the reinforcement of medicine localized delivery | RICHARDSON VICKS INC (US) | 1993-06-09 | — | — | CN | claimed |
| CN-1072602-A | Improve the enhanced dermal osmosis system of the local conveying of medicine | RICHARDSON VICKS INC (US) | 1993-06-02 | — | — | CN | claimed |
| WO-1993007902-A1 | ENHANCED SKIN PENETRATION SYSTEM FOR IMPROVED TOPICAL DELIVERY OF DRUGS | RICHARDSON-VICKS, INC. (US) | 1993-04-29 | — | — | WO | claimed |
| WO-1993007903-A1 | ENHANCED SKIN PENETRATION SYSTEM FOR IMPROVED TOPICAL DELIVERY OF DRUGS | RICHARDSON-VICKS, INC. (US) | 1993-04-29 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260097044-A1 | ION PAIR LIQUID CRYSTAL FORMULATIONS FOR LONG-ACTING INJECTABLES OF POORLY SOLUBLE DRUGS | SSB, LTB4R2, THRB | HRH3 872/4885MAOA 1744/4885HTR3A 393/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.